Press coverage about China Cord Blood (NYSE:CO) has been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. China Cord Blood earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 46.5021028712206 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

China Cord Blood (NYSE CO) opened at $10.53 on Thursday. The firm has a market capitalization of $1,291.67, a P/E ratio of 30.60 and a beta of 0.88. China Cord Blood has a 52-week low of $4.27 and a 52-week high of $14.95.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact China Cord Blood (CO) Stock Price” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/07/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-china-cord-blood-co-stock-price.html.

About China Cord Blood

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

Insider Buying and Selling by Quarter for China Cord Blood (NYSE:CO)

Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with MarketBeat.com's FREE daily email newsletter.